Skip to main content

Table 4 Univariate and multivariate survival analysis for NSCLC patients

From: The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt

  PFS
HR 95% CI p-value
Univariate
 Age 1.13 0.59–2.18 0.71
 Gender 0.84 0.40–1.73 0.63
 Smoking 0.73 0.38–1.40 0.35
 Grade 1.04 0.51–2.10 0.92
 T.size 1.62 0.78–3.35 0.19
 Laterality 1.29 0.93–1.79 0.13
 LN metastasis 1.65 1.17–2.34 0.005**
EGFR mutation 1.99 1.37–2.93 < 0.001***
 ROS1 0.95 0.61–1.47 0.81
 ALK 1.46 1.03–2.07 0.03*
 PD-1 1.36 0.81–2.29 0.24
 PD-L1 1.20 0.84–1.73 0.31
ROS1 rearrangement 1.09 0.70–1.69 0.70
Multivariate
 Laterality    
 LN metastasis 1.59 1.11–2.25 0.010*
 ALK 1.46 1.03–2.08 0.04*
EGFR 2.08 1.37–3.15 < 0.001***
  1. HR hazard ratio, PFS progression-free survival, LN lymph node, EGFR epidermal growth factor receptor, ROS1 c-ros oncogene1, ALK anaplastic lymphoma kinase, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1
  2. Cox regression analysis was used
  3. ***Significant at p < 0.001. **Significant at p < 0.01. *Significant at p < 0.05